|
Extracellular matrix (ECM) circulating peptide biomarkers as potential predictors of survival in patients (pts) with untreated metastatic pancreatic ductal adenocarcinoma (mPDA) receiving pegvorhyaluronidase alfa (PEGPH20), nab-paclitaxel (A), and gemcitabine (G). |
|
|
|
Stock and Other Ownership Interests - Halozyme |
|
|
Employment - Nordic Bioscience |
|
|
Employment - Nordic Bioscience |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Halozyme |
Research Funding - Halozyme |
Patents, Royalties, Other Intellectual Property - Johns Hopkins University |
Travel, Accommodations, Expenses - Halozyme |